Andrew Joseph

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. MADRID — With the first pivotal trial showing a customized mRNA treatment improved outcomes... See more

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of dr... See more

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of dr... See more

Liz covers cardiovascular and metabolic disease, asking why we're not doing better or even losing ground against the world's leading killer. Send tips on Signal at LizC.22. Since five members of the American Diabetes Association were ejected from its scie... See more

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. A multiple sclerosis treatment from Novartis cut by a third the rates of relapses that peop... See more